However, studies indicate that partial PPARγ agonists have lower risks of causing side effects (e.g., edema, fractures, and heart failure) relative to full PPARγ agonists, although they exhibit similar effects associated with insulin sensitivity. The gene discussed is PPARG; the disease is heart failure.